February 23, 2016 by Chain Drug Review
Apotex, Chip Davis, generic drugs, Generic Pharmaceutical Association, GPhA, GPhA’s 2016 board of directors, Heather Bresch, Jeff Watson, mylan, Par Pharmaceuticals, Tony Pera
Pharmacy, Supplier News
ORLANDO, Fla. — The Generic Pharmaceutical Association (GPhA) has elected Heather Bresch, chief executive officer of Mylan, to chair its board of directors this year. GPhA, which announced the move at its 2016 Annual Meeting here, also named other officers to its 2016 board and executive committee: Jeff Watson, president of global generics at Apotex,
February 11, 2016 by Chain Drug Review
Heather Bresch, Jörg-Thomas Dierks, Meda, mylan, Perrigo, Peter von Ehrenheim, Robert Coury
Leading Headlines, Pharmacy, Supplier News
HERTFORDSHIRE, England — Mylan N.V. plans to acquire Sweden-based pharmaceuticals manufacturer Meda AB in a deal valued at $9.9 billion, including debt. Mylan said late Wednesday that the offer to Meda includes cash and Mylan shares, with the equity portion valued at $7.2 billion. Executives from both companies noted that a Mylan-Meda combination would create
November 2, 2015 by Chain Drug Review
GlaxoSmithKline, GSK Consumer Healthcare, Heather Bresch, mylan, Rajiv Malik, Ranjan Ray Chaudhuri
Pharmacy, Supplier News
HERTFORDSHIRE, England, and PITTSBURGH — Mylan N.V. has tabbed GlaxoSmithKline Consumer Healthcare veteran Ranjan Ray Chaudhuri to serve as global commercial lead of Mylan’s over-the-counter business. Chaudhuri will report to Rajiv Malik, president of Mylan. “The opportunity to build upon Mylan’s one-of-a-kind global platform and contribute to the organization’s ongoing evolution is tremendously exciting to
September 14, 2015 by Chain Drug Review and Chain Drug Review
Heather Bresch, Joseph Papa, mylan, Perrigo, Robert Coury
Leading Headlines, Pharmacy, Supplier News
HERTFORDSHIRE, England — As promised, Mylan N.V. has proceeded to make formal bid to acquire Perrigo Co. plc in a deal valued at approximately $27 billion. Mylan said Monday that under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. That would translate to a
April 29, 2015 by Chain Drug Review and Chain Drug Review
Heather Bresch, Joe Papa, mylan, Perrigo, Robert Coury, Teva Pharmaceutical Industries
Supplier News
NEW YORK — Mylan N.V. has upped its offer to acquire Perrigo Co. plc but received the same response: no. On Wednesday, Mylan announced an increased bid in which Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share, a deal valued at more than $35 billion. But